Breast Cancer

The FDA has accepted a biologics license application for a proposed trastuzumab biosimilar. The therapy is being considered as adjuvant therapy for certain HER2-overexpressing cancers.

Precision medicine is a term that has been in our oncology language for years, but changes are occurring quickly. As oncology nurses, we need to learn about genomics and biomarkers and what precision medicine means for patients’ outcomes.

Kristin Daly, MSN, ANP-BC, AOCNP, discusses pathogenic variant testing and what it means for oncology nurses.

Isabel Octaviano, RN, details her role and experiences supporting patients during clinical trials.

La-Urshular Brock, MSN, FNP-BC, CNM, discusses how a better understanding of HER2-low status may necessitate more testing for certain patients with breast cancer.

Patritumab deruxtecan generated activity in patients with metastatic or unresectable EGFR-mutated non–small cell lung cancer and HER3-expressing breast cancer.

Patricia Jakel, RN, MN, AOCN discusses adverse event management in the age of new breast cancer treatments.

Lasofoxifene may be helpful in managing vaginal/vulvar symptoms in women with estrogen receptor–positive/HER2-negative breast cancer harboring an ESR1 mutation.

La-Urshalar Brock, MSN, FNP-BC, CNM, discusses HER2 status and its implications for patients with breast cancer.

Data from a retrospective analysis confirm the benefit of palbociclib plus an aromatase inhibitor in elderly patients with hormone receptor–positive, HER2-negative advanced/metastatic breast cancer.

Kristin M. Daly, MSN, ANP-BC, AOCNP, highlights the difference between somatic and germline variants.

Abemaciclib, in combination with endocrine therapy, had been approved as an adjuvant treatment for patients with high-risk, hormone receptor–positive, HER2-negative, node-positive, early breast cancer.

Sarah Donahue, MPH, AOCNP, cochair of the 40th Annual Miami Breast Cancer Conference nursing track, discusses the biggest updates in breast cancer from 2022.

Long-term data support a de-escalated dose of tamoxifen for certain women with breast intraepithelial neoplasia who are unable to receive the standard dose.

Triple-negative breast cancer often occurs in women younger than 40.

Oncology nurses provide perspective on the changing standards of care for patients with triple-negative breast cancer.

The National Comprehensive Cancer Network has updated their guidelines to include neratinib for patients with HER2-negative metastatic breast cancer.

The FDA has approved sacituzumab govitecan-hziy for patients with unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer.

The FDA has granted an accelerated approval to elacestrant (Orserdu) for the treatment of patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer following at least 1 prior lines of endocrine therapy.

Patients with breast cancer who carry BRCA1, BRCA2, CHEK2, or PALB2 germline pathogenic variants may be at a greater risk for contralateral breast cancer and may benefit from enhanced surveillance and risk-reduction strategies.

An analysis of 141 children who had prenatal exposure to maternal cancer showed promising cognitive and behavioral functions at age 9 years.

Jamie Carroll, APRN, CNP, MSN, offers her perspective on emerging data from the 2022 San Antonio Breast Cancer Symposium.

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP, reflects on data presented at the San Antonio Breast Cancer Symposium.

Patients with hormone receptor–positive, HER2-negative metastatic breast cancer derived benefit with sacituzumab govitecan regardless of Trop-2 expression.